An update on QT measurement and interpretation methodologies

Annals of Noninvasive Electrocardiology

Volumn 14, Issue SUPPL. 1, 2009, Pages

  Couderc, Jean Philippe ^a   Zareba, Wojciech ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; TERFENADINE;

CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; DRUG APPROVAL; DRUG INDUSTRY; EDITORIAL; ELECTROCARDIOGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL TECHNOLOGY; METHODOLOGY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REPOLARIZATION; RISK ASSESSMENT; TORSADE DES POINTES;

ELECTROCARDIOGRAPHY; HUMANS;

EID: 58449123550     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2008.00265.x     Document Type: Editorial

References (3)

1. Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997 273 (5 Pt 2 H2534 H2538.
2. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993 269 : 1532 1536.
3. ICH Harmonization Tripartie Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Available at : http://www.fda.gov/cder/guidance/6885fnl.htm 2007.